Clinical trials: Radiation Dosage
Enteritis
A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer
The purpose of this study is to evaluate the safety and preliminary efficacy of four doses of SGX201 in subjects with rectal cancer treated with concurrent radiation and chemotherapy.
- Trial name
- NCT01073384
- Testing
- SGX201 (delayed release beclomethasone 17,21-dipropionate)
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Soligenix
Mixed Gliomas, Malignant Gliomas
A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas
The purpose of this study is to determine the safety and tolerability of XL765 in combination with Temozolomide in adults with anaplastic gliomas or glioblastoma on a stable Temozolomide maintenance dose.
- Conditions
- Mixed Gliomas, Malignant Gliomas, Glioblastoma Multiforme
- Trial name
- NCT00704080
- Testing
- XL765 (SAR245409), Temozolomide
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sanofi
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected…
- Conditions
- GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
- Trial name
- NCT07165132
- Testing
- RYZ401
- Where
- 14 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- RayzeBio, Inc.
Glioblastoma
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent
- Trial name
- NCT05109728
- Testing
- [177Lu]Lu-DOTA-TATE, [68Ga]Ga-DOTA-TATE, Temozolomide
- Where
- 14 sites in United States, France and 3 more
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer With Metastatic Bone Disease
Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid
The aim of this prospective, randomized, open-label, multicentric clinical study is to assess the effícacy and tolerability of zoledronic acid 4 mg IV infused over 15 minutes every 4 weeks for a total of 6 infusions, in…
- Trial name
- NCT00172029
- Testing
- Zoledronic acid
- Where
- 7 sites in Turkey (Türkiye)
- Volunteers
- 116 people
- Sponsor
- Novartis
AMD, Wet AMD
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
The purpose of this study is to confirm the safety and establish the effectiveness of two doses from the IRay System for the treatment of wet AMD.
- Conditions
- AMD, Wet AMD, Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
- Trial name
- INTREPID (NCT01016873)
- Testing
- IRay
- Where
- 21 sites in Austria, Czechia and 3 more
- Volunteers
- 230 people
- Sponsor
- Oraya Therapeutics, Inc.
Advanced Solid Tumor, Intratumoral Injection
Phase I Study of RiMO-401 With Radiation in Advanced Tumors
This is a single arm study of RiMO-401 with radiation in patients with advanced tumors. A single escalation dose of RiMO-401 is intratumorally injected in a 3+3 study design to identify the recommended dose.
- Trial name
- NCT06182579
- Testing
- RiMO-401
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Coordination Pharmaceuticals, Inc.
Non-small Cell Lung Cancer (NSCLC)
Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases
A clinical study to investigate the maximum tolerated dose of Vandetanib and concurrent WBRT in patients with NSCLC and brain metastases. All patients will receive WBRT, 10 fractions of 3 Gy.
- Trial name
- NCT00807170
- Testing
- ZD6474 (Vandetanib), Whole Brain Radiotherapy (WBRT), ZD6474
- Where
- 3 sites in Netherlands
- Volunteers
- 5 people
- Sponsor
- Sanofi
Cancer
Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer
The study is intended as a Proof of Concept and dose confirmation study. The primary objective of this study is to observe safety and tolerability of idronoxil (NOX66) in combination with radiotherapy (at palliative doses) in…
- Trial name
- NCT03307629
- Testing
- NOX66, Irradiation Therapy
- Where
- 10 sites in Australia, Georgia and 1 more
- Volunteers
- 25 people
- Sponsor
- Noxopharm Limited
Carcinoma, Carcinoma, Hepatocellular
SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA
The goal of this interventional clinical trial is to evaluate the dose of radiation of Technetium-99m macroaggregated-albumin (99mTc-MAA) after an intra-arterial injection to the whole body and non-liver critical organs in…
- Conditions
- Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasm
- Trial name
- MAApping (NCT05848947)
- Testing
- 99mTc-Macro Albumin Aggregate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sirtex Medical
Enteritis Caused by Radiation
Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered SYN 020
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple-ascending-dose study to assess the PK, safety, and tolerability of SYN-020 oral delayed release capsules (SYN 020) in healthy adults.
- Trial name
- NCT05045833
- Testing
- SYN-020 Delayed Release Capsule
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Theriva Biologics, Inc.
Cancer, Lymphoma
Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
To evaluate whether palifermin (rHuKGF) administered as a single dose is non-inferior to 3 consecutive doses of palifermin in reducing the incidence of severe oral mucositis (World Health Organization [WHO] grade 3 and 4).
- Conditions
- Cancer, Lymphoma, Leukemia
- Trial name
- NCT00109031
- Testing
- palifermin, Total Body Irradiation, Cyclophosphamide
- Volunteers
- 47 people
- Sponsor
- Swedish Orphan Biovitrum
Newly Diagnosed and Recurrent Glioblastoma
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
This study will investigate different doses of [177Lu]Lu-NeoB in combination with RT and TMZ in participants with newly diagnosed glioblastoma, with methylated or unmethylated promoter, to assess the safety and efficacy of…
- Trial name
- NCT05739942
- Testing
- [177Lu]Lu-NeoB, [68Ga]Ga-NeoB, Temozolomide
- Where
- 16 sites in United States, France and 4 more
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer, Metastases
Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton
The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of three intravenous escalating dose levels of Xofigo (Alpharadin).
- Conditions
- Prostate Cancer, Metastases, Pharmacokinetics
- Trial name
- NCT00748046
- Testing
- Radium-223 chloride (BAY88-8223)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Bayer
Mucositis, Solid Tumors
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
The purpose of this research study is to test the safety and effectiveness of palifermin to determine if weekly doses can be safely administered to reduce the incidence (occurrence of), duration (length of time) and severity…
- Conditions
- Mucositis, Solid Tumors, Stomatitis, Head and Neck Cancer
- Trial name
- NCT00101582
- Testing
- palifermin, cisplatin chemotherapy, Radiotherapy
- Volunteers
- 188 people
- Sponsor
- Swedish Orphan Biovitrum
Nausea and Vomiting, Testicular Germ Cell Tumor
Lerisetron Compared With Granisetron in Preventing Nausea and Vomiting in Men Being Treated With Radiation Therapy for Stage I Seminoma
RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients treated with radiation therapy. It is not yet known whether lerisetron is more effective than granisetron in preventing nausea and…
- Trial name
- NCT00004219
- Testing
- granisetron hydrochloride, lerisetron, radiation therapy
- Volunteers
- 150 people
- Sponsor
- Simbec Research
Stomatitis
Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy
Radiotherapy and high dose chemotherapy with bone marrow transplantation or peripheral blood stem cell transplantation is frequently used as treatment for patients with cancers of the bone marrow or lymph nodes such as Hodgkin's…
- Trial name
- NCT00041665
- Testing
- Recombinant Human Keratinocyte Growth Factor
- Sponsor
- Amgen
Glioblastoma
A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma
This study is open to adults with newly diagnosed glioblastoma, a type of brain tumor. The study has two parts. Part 1 is open to people who can get their brain tumor removed by surgery.
- Trial name
- NCT05376800
- Testing
- BI 907828 (Brigimadlin)
- Where
- 7 sites in United States, Belgium and 1 more
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Ototoxicity
Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment
The purpose of this study is to evaluate whether DB-020 administered via an injection in the middle ear prevents hearing loss in participants who will receive high doses of cisplatin as part of their treatment for cancer.
- Trial name
- NCT04262336
- Testing
- DB-020
- Where
- 8 sites in United States, Australia
- Volunteers
- 22 people
- Sponsor
- Decibel Therapeutics
Bone Metastases in the Thorax
FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax
The purpose of this study is to assess toxicities of FLASH radiotherapy treatment and pain relief in subjects with painful thoracic bone metastases.
- Trial name
- FAST-02 (NCT05524064)
- Testing
- FLASH Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Varian, a Siemens Healthineers Company